Search

Copyright of Journal of Ordnance Equipment Engineering is the property of Chongqing University of Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Lubrication Engineering (0254-0150) is the property of Editorial Office of LUBRICATION ENGINEERING and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Lubrication Engineering (0254-0150) is the property of Editorial Office of LUBRICATION ENGINEERING and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Transportation Science & Technolgy is the property of Transportation Science & Technology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Engineering for Thermal Energy & Power / Reneng Dongli Gongcheng is the property of Journal of Engineering for Thermal Energy & Power and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To observe the effect of ibandronate intervention on glucocorticoid-induced bone metabolism index in patients with osteoporosis. Methods Forty-eight patients with glucocorticoid-induced osteoporosis treated in our hospital from January to December 2017were as subjects. They were randomly divided into comparison group (24 cases) and observation group (24 cases). The patients in two groups received Caltrate treatment (0． 5 μg / twice a day, for 12 weeks). Patients in observation group received additional intravenous ibandronate (initiate 2 mg, then 3 mg / month, for 3 months). The differences of serum PTH, BALP, BGP, CTX-1, and tPINP were compared between the two groups before and after the treatment. Results There was no difference of PTH, BALP, BGP, CTX-1, and tPINP between the comparison group and the observation group before the treatment (P>0． 05). Compared with those before treatment, the expression levels of BALP and PTH in the observation group and the comparison group were significantly up-regulated, and the expression levels of BGP, CTX-1, and t PINP were significantly down regulated (P<0． 05). Compared with the comparison group, the expression levels of BALP and PTH increased significantly in the observation group after treatment, and the expression levels of BGP, CTX-1, and tPINP decreased significantly (P <0． 05). Conclusion Ibandronate treatment significantly releases the abnormal expression of serum PTH, promotes bone resorption and bone formation, in patients with glucocorticoid-induced osteoporosis. This may be the target of the treatment of glucocorticoidinduced osteoporosis. [ABSTRACT FROM AUTHOR]